For plaque or guttate psoriasis, home-based narrowband ultraviolet B phototherapy is as effective as office-based ...

Zasocitinib at doses of 5 mg or greater vs placebo resulted in greater skin clearance among patients with moderate to severe plaque psoriasis.

Your psoriasis symptoms might include: small or large areas of irritated ... Most children with psoriasis will develop a few plaques that may be easily addressed with treatment.

Plaque psoriasis, the most common form of the disease ... While these individuals may have a relatively small BSA involved, the location of the lesions often prevents patients from participating ...

Known as psoriasis plaques, these lesions can be painful and itchy and can be a source of significant physical and psychological distress. As a chronic condition, daily life often revolves around ...

Many patients struggle with therapeutic control, adverse effects, and costs of psoriasis treatments, prompting a renewed ...

Some patients with psoriasis who were treated with guselkumab and achieved complete skin clearance experienced a persistent impact on quality of life.

When compared with placebo and apremilast, patients with plaque psoriasis receiving deucravacitinib had improved patient-reported signs, symptoms, and quality of life through 52 weeks of continuous ...

Dermavant’s novel product, Vtama (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the FDA in May 2022. Vtama cream is a ...

The "Plaque Psoriasis: Seven-Market Drug Forecast Analysis - Update" report has been added to ResearchAndMarkets.com's offering. This publication is an update to the report Plaque Psoriasis: Global ...

Johnson & Johnson's stock has seen modest gains in recent months. Read why I downgrade JNJ stock from buy to hold.

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...